Optas, LLC Vertex Pharmaceuticals Inc Transaction History

Optas, LLC

$429 Million
Q3 2024

A detailed history of Optas, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Optas, LLC holds 810 shares of VRTX stock, worth $406,393. This represents 0.09% of its overall portfolio holdings.

Number of Shares

810

Previous 773 4.79%

Holding current value

$406,393

Previous $362,000 3.87%

% of portfolio

0.09%

Previous 0.09%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 29, 2024	BUY	$460.0 - $505.78 $17,020 - $18,713	37 Added 4.79%	810 $376,000
Q2 2024 Jul 25, 2024	BUY	$392.81 - $485.53 $7,463 - $9,225	19 Added 2.52%	773 $362,000
Q1 2024 Apr 17, 2024	BUY	$407.69 - $446.08 $3,669 - $4,014	9 Added 1.21%	754 $315,000
Q4 2023 Jan 25, 2024	BUY	$343.0 - $410.68 $3,430 - $4,106	10 Added 1.36%	745 $303,000
Q3 2023 Oct 31, 2023	BUY	$338.18 - $362.46 $6,425 - $6,886	19 Added 2.65%	735 $255,000
Q2 2023 Jul 20, 2023	BUY	$314.42 - $351.91 $2,829 - $3,167	9 Added 1.27%	716 $251,000
Q1 2023 Apr 17, 2023	BUY	$283.23 - $323.1 $200,243 - $228,431	707 New	707 $222,000
Q4 2020 Jan 27, 2021	SELL	$207.01 - $276.09 $279,670 - $372,997	-1,351 Closed	0 $0
Q3 2020 Oct 23, 2020	BUY	$255.65 - $303.1 $119,899 - $142,153	469 Added 53.17%	1,351 $367,000
Q2 2020 Jul 31, 2020	SELL	$225.48 - $295.8 $30,439 - $39,933	-135 Reduced 13.27%	882 $256,000
Q1 2020 Apr 14, 2020	BUY	$199.77 - $247.81 $1,797 - $2,230	9 Added 0.89%	1,017 $241,000
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $168,043 - $225,701	1,008 New	1,008 $220,000

Others Institutions Holding VRTX

# of Institutions

1,717

Shares Held

226M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Optas, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Optas, LLC with notifications on news.

Account